Table 1.
QRS <150 ms (n=139) |
QRS ⩾150 ms (n=26) | All patients (n=165) |
|
Male/female (%) | 80.6/19.4 | 76.9/23.1 | 80.0/20.0 |
Age (years) (mean (SD)) | 61.8 (9.7) | 61.7 (9.9) | 61.8 (9.7) |
Age range (years) | 14–82 | 31–79 | 14– 82 |
EF (%) (mean (SD)) | 32.9 (13.3) | 30.6 (15.0) | 32.5 (13.6) |
EF range (%) | 7 to 83 | 10 to 61 | 7 to 83 |
Underlying disease (n) | |||
CAD | 104 (74.8%) | 16 (61.5%) | 120 (72.7%) |
DCM | 24 (17.3%) | 5 (19.2%) | 29 (17.6%) |
ARVCM | 3 (2.2%) | 1 (3.8%) | 4 (2.4%) |
Valvar | 5 (3.6%) | 4 (15.4%) | 9 (5.5%) |
Other | 3 (2.2%) | – | 3 (1.8%) |
Presenting arrhythmia (n) | |||
CA | 86 (61.7%) | 18 (69.1%) | 104 (63.0%) |
Only VT | 51 (36.7%) | 9 (34.6%) | 60 (36.4%) |
Only VF | 50 (36.0%) | 8 (30.8%) | 58 (35.2%) |
VT+VF | 29 (20.9%) | 8 (30.8%) | 37 (22.4%) |
Others | 9 (6.5%) | 1 (3.8%) | 10 (6.1) |
Drug treatment (n) | |||
Class I AA drugs | 2 (1,5%) | – | 2 (1.3%) |
Class III AA drugs | 30 (22.6%) | 8 (33.3%) | 38 (24.2%) |
β Blocker | 38 (28.4%) | 3 (12.5%) | 41 (25.9%) |
ACE inhibitor | 94 (70.1%) | 21 (87.5%) | 115 (72.8%) |
Diuretic | 89 (66.4%) | 19 (79.2%) | 108 (68.4%) |
Digitalis | 102 (76.1%) | 20 (83.3%) | 122 (77.2%) |
Lead system (n) | |||
Transvenous | 84 (60.4%) | 18 (69.2%) | 102 (61.8%) |
Transvenous-subcutaneous | 53 (38.1%) | 8 (30.8%) | 61 (37.0%) |
Epicardial | 2 (1.4%) | – | 2 (1.2%) |
AA, antiarrhythmic; ACE, angiotensin converting enzyme; ARVCM, arrhythmogenic right ventricular cardiomyopathy; CA, cardiac arrest; CAD, coronary artery disease; DCM, dilated cardiomyopathy;
EF, ejection fraction; VF, ventricular fibrillation; VT, ventricular tachycardia.